The Lung session of the 2017 14th Banff Foundation for Allograft Pathology Conference,
Barcelona focused on the multiple aspects of antibody-mediated rejection (AMR) in lung …

Allograft rejection remains the major hurdle in lung transplantation despite modern
immunosuppressive treatment. As part of the alloreactive process, B cells are increasingly …

Antibody-mediated rejection (AMR) is a principal cause of acute and chronic failure of lung
allografts. However, mechanisms mediating this oftentimes fatal complication are poorly …

Circulating exosomes containing donor HLA and lung-associated self-antigens (SAg) are
thought to play an important role in allograft rejection after human lung transplantation. We …

Donor-specific antibodies (DSA) to mismatched human leukocyte antigens (HLA) are
associated with worse outcomes after lung transplantation. To determine the incidence and …

Antibody-mediated rejection (AMR) has been identified as a significant form of acute
allograft dysfunction in lung transplantation. The development of consensus diagnostic …

Although chronic lung allograft dysfunction (CLAD) remains the major life-limiting factor
following lung transplantation, much of its pathophysiology remains unknown. The discovery …

Lung transplantation improves survival and quality of life in patients with advanced
pulmonary disease. Over the past several decades, the volume of lung transplants has …

Background Pulmonary antibody-mediated rejection (AMR) consensus criteria categorize
AMR by diagnostic certainty. This study aims to define the clinical features and associated …

Long term outcomes in lung transplant are limited by the development of chronic lung
allograft dysfunction (CLAD). Within the past several decades, antibody-mediated rejection …